5.1.2021 10:47:01 CET | Aqua Bio Technology ASA | Non-regulatory press releases

ABT expects the Balance & Vitality product series to be ready for distribution
and sale in the first half of 2021.

Reference is made to the stock exchange announcement of 26 November 2020
[https://live.euronext.com/nb/listview/company-press-release/146254#CompanyPress
Release-3399797] regarding ongoing safety studies for the Nordic Beauty and
Balance & Vitality product series. We have today received confirmation that the
first 25 products from Balance & Vitality have passed the safety studies that
the EU requires to be carried out before commercialization. The results for the
last 3 products are expected to be approved during Q1 2021. Since the last stock
exchange announcement about the development of the products, the Balance &
Vitality series have increased from 27 to 28 products. Balance & Vitality will
be a complete skincare series with products in all categories. The tests were
performed at Eurofins [https://www.eurofins.com/about-us/], which is the world's
largest in testing food, environment, medicine and cosmetics and has 800
laboratories in more than 50 different countries. 

ABT expects the Balance & Vitality product series to be ready for distribution
and sale in the first half of 2021. 

For further information, please contact Espen Kvale, CEO, telephone +47 916 28
092.

Aqua Bio Technology (ABT) is developing and commercializing sustainable
biotechnology for use in skin care products. ABT's cosmetics ingredients are
effective and they provide the cosmetics industry with natural alternatives to
traditional ingredients. ABT is also marketing and distributing natural skin
care products developed by partners towards consumers and professional users.
ABT's focus on commercialization and development of natural ingredients and
natural skin care products has been, and will continue to be, an important part
of the company's strategy going forward. Aqua Bio Technology is listed on
Euronext Expand.

 

CONTACTS

 * Espen Kvale, CEO, +47 916 28 092, espen.kvale@aquabiotech.no 

ATTACHMENTS

 * Download announcement as PDF.pdf
   [https://kommunikasjon.ntb.no/ir-files/17847556/244/289/Download%20announceme
   nt%20as%20PDF.pdf]

Click here for more information

© Oslo Bors ASA, source Oslo Stock Exchange